|Bid||74.00 x 800|
|Ask||75.52 x 1300|
|Day's Range||70.19 - 75.70|
|52 Week Range||56.39 - 226.14|
|Beta (5Y Monthly)||0.88|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 29, 2022 - Aug 08, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||102.75|
Subscribe to Yahoo Finance Plus to view Fair Value for NVCR
NovoCure (NVCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
ST. HELIER, Jersey, June 21, 2022--Novocure (NASDAQ: NVCR) today announced the first patient has been enrolled in its phase 2 pilot KEYNOTE-B36 study, conducted in collaboration with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA. KEYNOTE-B36 is designed to evaluate the safety and effectiveness of Tumor Treating Fields (TTFields) together with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, for the first-line treatment of locally advanced or metastatic intrathoracic non-small cell lu
Shares of Novocure (NASDAQ: NVCR) were plunging 18.5% this week as of the market close on Thursday, according to data from S&P Global Market Intelligence. Novocure was a victim of the broader market sell-off this week. Both indexes tumbled over the past few days as the Federal Reserve raised interest rates by the highest amount in decades as part of an effort to fight skyrocketing inflation.